Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN73,0673,091,25
Msft0,37
Nokia4,5694,638-2,55
IBM0,14
Mercedes-Benz Group AG52,7152,73-0,36
PFE0,17
31.05.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 29.05.2025
AxoGen (LT3.BE, Berlin)
Závěr k 29.5.2025 Změna (%) Změna (EUR) Objem obchodů (EUR)
9,65 -3,50 -0,35 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.06.2025
Popis společnosti
Obecné informace
Název společnostiAxoGen Inc
TickerAXGN
Kmenové akcie:Ordinary Shares
RICAXGN.O
ISIN-
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 451
Akcie v oběhu k 05.05.2025 45 544 044
MěnaUSD
Kontaktní informace
UliceSUITE 100, 13859 PROGRESS BLVD.
MěstoALACHUA
PSČ32615
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 864 626 817
Fax13864626801

Business Summary: Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
Financial Summary: BRIEF: For the three months ended 31 March 2025, AxoGen Inc revenues increased 17% to $48.6M. Net loss decreased 42% to $3.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Peripheral nerves segment loss decrease of 64% to $1.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.08.
Odvětvová klasifikace
TRBC2009Medical Equipment / Supplies / Distribution
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Medical Equipment, Supplies & Distribution
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Electromedical Apparatus Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICElectromedical Equipment
SICElectromedical Equipment
SICCommercial Physical Research



  • Poslední aktualizace: 01.06.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorMichael Dale6509.08.202409.08.2024
Chief Financial OfficerLindsey Hartley-12.05.202512.05.2025
Executive Vice President, Chief Compliance Officer, General CounselMarc Began58
Chief Marketing OfficerJens Kemp4813.02.202313.02.2023
Vice President - Global Health Economics, Reimbursement & PolicyRick Ditto-24.03.202524.03.2025
Chief Innovation OfficerErick Devinney49